ScreenPoint Medical has successfully raised 13.6 million euros to further develop its artificial intelligence tools for breast cancer screening. The Nijmegen-based firm secured 11.9 million euros in a funding round led by existing investors Insight Partners and Siemens Healthineers. This capital is joined by 1.7 million euros in non-dilutive research grants. The Dutch company intends to use the total investment to drive product innovation and push into more international markets.
The firm is known for its Transpara software suite which assists radiologists in reviewing 2D and 3D mammograms. This technology aims to improve the accuracy of early cancer detection while making screening workflows more efficient for medical staff. Currently Transpara is used in more than 30 countries and has processed over 12 million mammograms. Clinical research published in The Lancet has previously validated the technology. The MASAI trial showed that the AI performed better than the standard method of two radiologists reading the same scan.
ScreenPoint Medical was founded in 2014 by Professors Nico Karssemeijer and Sir Michael Brady as a spin-off from Radboud University Medical Centre in the Netherlands. The company focuses on creating a more personalised approach to patient care. CEO Pieter Kroese commented on the new funding.
“This investment endorses our strategy and our shared success. We are well-positioned to scale globally and accelerate the development of solutions that make care personal and powerful. Our goal is to support clinicians and women across the full continuum of breast cancer care,” said Kroese.
Dr Robert Epstein, Health Care Senior Advisor at Insight Partners, noted the impact of the technology on both patients and the wider population.
“ScreenPoint Medical continues to lead and innovate in applying AI to breast imaging. The opportunity to create a greater level of personalised care is vast and clinically impactful at both a patient and population level. We are excited to support ScreenPoint Medical as it builds an integrated and comprehensive approach,” said Epstein.
